ESMO scientific and educational resources on this topic
Recent medwireNews and resources from conferences are for ESMO Members only.
Melanoma and other Skin Tumours
Latest ESMO videos
Featured medwireNews
Long-Term COLUMBUS Data Confirm Encorafenib–Binimetinib PFS Benefit in Advanced Melanoma
Adjuvant PD-1 Inhibitor Chronic Immune-Related AEs Highlighted In Advanced Melanoma
Stage III High-Risk Melanoma Benefits With Dabrafenib–Trametinib, Pembrolizumab
Continuous BRAF–MEK inhibition Best For BRAF-Mutated Melanoma
Immune-Related Adverse Event Risks Differ By ICI Regimen in Advanced Melanoma
E-Learning
ESMO E-Learning: Metastatic Melanoma Treatment
ESMO V-Learning: BRAF Mutations Across Cancers
ESMO V-Learning: Inhibition of MEK to Treat Cancer, focussing on Melanoma
Factsheets on Biomarkers
PD-L1 in Cancer: ESMO Biomarker Factsheet
NRAS in Melanoma: ESMO Biomarker Factsheet
BRAF in Melanoma: ESMO Biomarker Factsheet
Meeting resources
1041MO - 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma
Presenter: Reinhard Dummer
Session: Mini oral session - Melanoma and other skin tumours
Resources:
Abstract
LBA40 - SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study
Presenter: Paolo Ascierto
Session: Mini oral session - Melanoma and other skin tumours
Resources:
Abstract
LBA39 - Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage IIIB-D melanoma patients (pts) stratified according to the interferon-gamma signature (IFN-γ sign): The DONIMI study
Presenter: Christian Blank
Session: Mini oral session - Melanoma and other skin tumours
Resources:
Abstract
1039MO - CheckMate 204: 3-year outcomes of treatment with combination nivolumab (NIVO) plus ipilimumab (IPI) for patients (pts) with active melanoma brain metastases (MBM)
Presenter: Kim Margolin
Session: Mini oral session - Melanoma and other skin tumours
Resources:
Abstract
1038MO - Intracranial activity of encorafenib and binimetinib followed by radiotherapy in patients with BRAF mutated melanoma and brain metastasis: Preliminary results of the GEM1802/EBRAIN-MEL phase II clinical trial
Presenter: Ivan Marquez-Rodas
Session: Mini oral session - Melanoma and other skin tumours
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.